Originally launched in April 2020 under the aegis of the Research Luxembourg COVID-19 Taskforce, the CON-VINCE study aims to evaluate the prevalence and dynamics of the spread of Covid-19 within the Luxembourgish population, having tested a panel of 1,800 participants, representative of the Luxembourgish population.

Now, one year after the study launched, the last round of testing of the CON-VINCE participants is due to start in April 2021. The final wave will provide a comprehensive insight into the evolution and transmission of the disease over an extended timeframe, particularly from an immunity perspective.

Under the leadership of Prof Rejko Krüger, Director of Transversal Translational Medicine (TTM) at the Luxembourg Institute of Health (LIH), CON-VINCE aims to detect asymptomatic and mildly symptomatic (oligosymptomatic) carriers by testing a panel of over 1,800 individuals, representative of the Luxembourgish population, for the presence of the SARS-CoV-2 virus and monitoring them over 12 months through a series of follow-up visits.

Follow-up testing will commence on 19 April for a duration of five weeks. Collected nasopharyngeal swabs will undergo PCR testing to detect the presence of the SARS-CoV-2 virus, while blood samples will be analysed for antibodies (serological testing) to assess whether the participants have mounted an immune response following exposure to the virus or after vaccination. Tests carried out among the population in late 2020 showed that an estimated 7% of residents had antibodies.

Only participants previously enrolled in CON-VINCE will be contacted. The study is not recruiting any new volunteers.